Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes

被引：1

作者：

Hu, Yuxuan ^{[1
]}

Wang, Yanning ^{[2
]}

Shao, Taihang ^{[3
]}

Tang, Wenxi ^{[3
]}

Hu, Kerong ^{[4
]}

Zhou, Yujie ^{[5
]}

Miao, Liyun ^{[5
]}

Liu, Jing ^{[6
]}

Wang, Bin ^{[2
]}

Yu, Wenying ^{[1
]}

机构：

[1] China Pharmaceut Univ, Inst Pharmaceut Sci, Nanjing 211198, Peoples R China

[2] Nanjing Univ, Affiliated Drum Tower Hosp, Clin Stem Cell Ctr, Med Sch, 321 Zhongshan Rd, Nanjing 210008, Peoples R China

[3] China Pharmaceut Univ, Sch Int Pharmaceut Business, Dept Pharmacoecon, Nanjing 211198, Peoples R China

[4] Huangshi Love & Hlth Hosp, Dept Infect Dis, Huangshi 435000, Peoples R China

[5] Nanjing Drum Tower Hosp, Dept Resp & Crit Care Med, Nanjing 210008, Peoples R China

[6] Nanjing Yuhua Hosp, Nanjing Hosp 1, Yuhua Branch, Clin Lab, Nanjing 210039, Peoples R China

来源：

VACCINE | 2023年 / 41卷 / 18期

关键词：

COVID-19; SARS-CoV-2; Heterologous vaccination; Immunogenicity; Meta-analysis; NCOV-19;

D O I：

10.1016/j.vaccine.2023.03.056

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Introduction: Here, we systematically assessed the safety and immunogenicity of the heterologous ChAd/ BNT vaccination regimens.Materials and methods: We evaluated the immunogenicity by the geometric mean titers ratio (GMTR) of the neutralizing antibody and anti-spike IgG. The safety of heterologous ChAd/BNT vaccination was evaluated using the pooled risk ratios (RRs) calculated by the random-effects model about the adverse events. Our study was registered with PROSPERO, CRD42021265165.Results: Eleven studies were included in the analyses. Compared to the homologous ChAd/ChAd vaccination, the heterologous ChAd/BNT vaccination showed significantly higher immunogenicity in terms of the neutralizing antibody and GMTR of anti-spike IgG, but at the same time displayed higher incidence of total adverse reactions, especially for the local adverse reactions. Moreover, heterologous ChAd/BNT vaccination showed similar immunogenicity to the homologous BNT/BNT vaccination (GMTR of neutralizing antibody and anti-spike IgG) and similar safety.Discussion: Heterologous ChAd/BNT vaccination showed robust immunogenicity and tolerable safety. (c) 2023 Elsevier Ltd. All rights reserved.

引用

页码：3003 / 3010

页数：8

共 50 条

[1] Heterologous ChAdOx1-nCoV19-BNT162b2 vaccination provides superior immunogenicity against COVID-19
Richardson, Christopher D.
LANCET RESPIRATORY MEDICINE, 2021, 9 (11): : 1207 - 1209
[2] Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
Bruno Pozzetto
Vincent Legros
Sophia Djebali
Véronique Barateau
Nicolas Guibert
Marine Villard
Loïc Peyrot
Omran Allatif
Jean-Baptiste Fassier
Amélie Massardier-Pilonchéry
Karen Brengel-Pesce
Melyssa Yaugel-Novoa
Solène Denolly
Bertrand Boson
Thomas Bourlet
Antonin Bal
Martine Valette
Thibault Andrieu
Bruno Lina
François-Loïc Cosset
Stéphane Paul
Thierry Defrance
Jacqueline Marvel
Thierry Walzer
Sophie Trouillet-Assant
Nature, 2021, 600 : 701 - 706
[3] Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
Tenbusch, Matthias
Schumacher, Sofie
Vogel, Emanuel
Priller, Alina
Held, Juergen
Steininger, Philipp
Beileke, Stephanie
Irrgang, Pascal
Brockhoff, Ronja
Salmanton-Garcia, Jon
Tinnefeld, Kathrin
Mijocevic, Hrvoje
Schober, Kilian
Bogdan, Christian
Yazici, Sarah
Knolle, Percy
Cornely, Oliver A.
Ueberla, Klaus
Protzer, Ulrike
LANCET INFECTIOUS DISEASES, 2021, 21 (09): : 1212 - 1213
[4] BNT162b2 boosted neutralizing antibody titers after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination
Hammerschmidt, S. I.
Barros-Martins, J.
Cossmann, A.
Ramos, G. Morillas
Stankow, M. V.
Odak, I.
Dopfer-Jablonka, A.
Hetzel, L.
Koehler, M.
Patzer, G.
Binz, C.
Ritter, C.
Friedrichsen, M.
Schultze-Florey, C.
Ravens, I.
Willenzon, S.
Bubke, A.
Ristenpart, J.
Janssen, A.
Ssebyatika, G.
Kraehling, V.
Bernhardt, G.
Hoffmann, M.
Poehlmann, S.
Krey, T.
Bosnjak, B.
Foester, R.
Behrens, G. M. N.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 154 - 155
[5] Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Reiter, Rieke
Von Blanckenburg, Pia
Mutters, Reinier
Thiemer, Julia
Gessner, Reinhard
Seifart, Ulf
VACCINES, 2022, 10 (05)
[6] BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Behrens, Georg M. N.
Barros-Martins, Joana
Cossmann, Anne
Ramos, Gema Morillas
Stankov, Metodi, V
Odak, Ivan
Dopfer-Jablonka, Alexandra
Hetzel, Laura
Koehler, Miriam
Patzer, Gwendolyn
Binz, Christoph
Ritter, Christiane
Friedrichsen, Michaela
Schultze-Florey, Christian
Ravens, Inga
Willenzon, Stefanie
Bubke, Anja
Ristenpart, Jasmin
Janssen, Anika
Ssebyatika, George
Kraehling, Verena
Bernhardt, Guenter
Hoffmann, Markus
Poehlmann, Stefan
Krey, Thomas
Bosnjak, Berislav
Hammerschmidt, Swantje, I
Foerster, Reinhold
NATURE COMMUNICATIONS, 2022, 13 (01)
[7] BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
Georg M. N. Behrens
Joana Barros-Martins
Anne Cossmann
Gema Morillas Ramos
Metodi V. Stankov
Ivan Odak
Alexandra Dopfer-Jablonka
Laura Hetzel
Miriam Köhler
Gwendolyn Patzer
Christoph Binz
Christiane Ritter
Michaela Friedrichsen
Christian Schultze-Florey
Inga Ravens
Stefanie Willenzon
Anja Bubke
Jasmin Ristenpart
Anika Janssen
George Ssebyatika
Verena Krähling
Günter Bernhardt
Markus Hoffmann
Stefan Pöhlmann
Thomas Krey
Berislav Bošnjak
Swantje I. Hammerschmidt
Reinhold Förster
Nature Communications, 13
[8] BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes
Abdul-Jawad, Sultan
Beatson, Richard
Lechmere, Thomas
Graham, Rosalind
Alaguthurai, Thanussuyah
Graham, Carl
Vidler, Jennifer
Kulasekararaj, Austin
Patten, Piers E. M.
Doores, Katie J.
Irshad, Sheeba
HAEMATOLOGICA, 2022, 107 (05) : 1181 - 1184
[9] Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19-BNT162b2 mRNA Vaccination
Catry, Emilie
Favresse, Julien
Gillot, Constant
Bayart, Jean-Louis
Frerotte, Damien
Dumonceaux, Michel
Evrard, Patrick
Mullier, Francois
Douxfils, Jonathan
Carlier, Francois M.
Closset, Melanie
VIRUSES-BASEL, 2022, 14 (07):
[10] Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination
Pozzetto, Bruno
Legros, Vincent
Djebali, Sophia
Barateau, Veronique
Guibert, Nicolas
Villard, Marine
Peyrot, Loic
Allatif, Omran
Fassier, Jean-Baptiste
Massardier-Pilonchery, Amelie
Brengel-Pesce, Karen
Yaugel-Novoa, Melyssa
Denolly, Solene
Boson, Bertrand
Bourlet, Thomas
Bal, Antonin
Valette, Martine
Andrieu, Thibault
Lina, Bruno
Cosset, Francois-Loic
Paul, Stephane
Defrance, Thierry
Marvel, Jacqueline
Walzer, Thierry
Trouillet-Assant, Sophie
NATURE, 2021, 600 (7890) : 701 - +

← 1 2 3 4 5 →